NASDAQ:PRAN - Prana Biotechnology Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $2.2150 -0.03 (-1.34 %) (As of 07/22/2018 04:17 AM ET)Previous Close$2.2150Today's Range$2.1501 - $2.2652-Week Range$1.75 - $3.79Volume6,957 shsAverage Volume198,825 shsMarket Capitalization$19.93 millionP/E Ratio-3.46Dividend YieldN/ABeta-0.09 Company ProfileFinancialsAnalyst RatingsHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Prana Biotechnology Limited develops therapies for the treatment of Alzheimer's disease, Huntington disease, and other neurodegenerative disorders in Australia. Its lead drug candidates include PBT2, which is in Phase IIb clinical trials for the treatment of Alzheimer's: and that is in Phase IIa clinical trials for the treatment of Huntington's diseases. The company is also developing PBT434, which is in preclinical toxicology stage for the treatment for Parkinson's disease and other movement disorders; and PBT 519 that is in preclinical toxicology stage for the treatment of brain cancer. It also has a library of approximately 1000 metal protein attenuating compounds. The company has a research collaboration agreement with Takeda Pharmaceuticals International, Inc. to slow or prevent neurodegeneration of the gastrointestinal system through PBT434, an investigational movement disorders compound. Prana Biotechnology Limited was founded in 1997 and is based in Melbourne, Australia. Receive PRAN News and Ratings via Email Sign-up to receive the latest news and ratings for PRAN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:PRAN CUSIPN/A Webwww.pranabio.com Phone61-3-9349-4906 Debt Debt-to-Equity RatioN/A Current Ratio12.11 Quick RatioN/A Price-To-Earnings Trailing P/E Ratio-3.46 Forward P/E Ratio-2.77 P/E GrowthN/A Sales & Book Value Annual Sales$100,000.00 Price / Sales197.14 Cash FlowN/A Price / CashN/A Book Value$2.01 per share Price / Book1.10 Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees9 Outstanding Shares8,900,000Market Cap$19.93 Prana Biotechnology (NASDAQ:PRAN) Frequently Asked Questions What is Prana Biotechnology's stock symbol? Prana Biotechnology trades on the NASDAQ under the ticker symbol "PRAN." When is Prana Biotechnology's next earnings date? Prana Biotechnology is scheduled to release their next quarterly earnings announcement on Thursday, August, 30th 2018. View Earnings Estimates for Prana Biotechnology. What price target have analysts set for PRAN? 1 analysts have issued 12-month price targets for Prana Biotechnology's shares. Their forecasts range from $4.00 to $4.00. On average, they anticipate Prana Biotechnology's stock price to reach $4.00 in the next year. This suggests a possible upside of 80.6% from the stock's current price. View Analyst Ratings for Prana Biotechnology. What is the consensus analysts' recommendation for Prana Biotechnology? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prana Biotechnology in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." Who are some of Prana Biotechnology's key competitors? Some companies that are related to Prana Biotechnology include Axsome Therapeutics (AXSM), Vernalis (VNLPY), VIVUS (VVUS), Trillium Therapeutics (TRIL), Novan (NOVN), Advaxis (ADXS), Pharmaxis Limited ADR Common Stock (PXSLY), Aquinox Pharmaceuticals (AQXP), Alimera Sciences (ALIM), Versartis (VSAR), Merrimack Pharmaceuticals (MACK), IMMUTEP LTD/S (IMMP), KemPharm (KMPH), OncoSec Medical (ONCS) and Humanigen (HGEN). Who are Prana Biotechnology's key executives? Prana Biotechnology's management team includes the folowing people: Mr. Geoffrey Paul Kempler B.Sc, Grad.Dip.App.Soc.Psych, Co-Founder, Exec. Chairman, CEO & MD (Age 63)Ms. Kathryn Andrews B.Com, CPA, Chief Financial Officer (Age 51)Ms. Dianne M. Angus, Chief Operating Officer (Age 58)Dr. David A. Stamler M.D., Chief Medical Officer, Sr. VP of Clinical Devel. and Member of R&D Advisory Board (Age 57)Prof. Rudolph Emile Tanzi Ph.D., Chief Scientific Advisor and Member of R&D Advisory Board Has Prana Biotechnology been receiving favorable news coverage? Media stories about PRAN stock have been trending somewhat positive on Sunday, Accern Sentiment reports. The research firm scores the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Prana Biotechnology earned a news sentiment score of 0.24 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 46.36 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term. How do I buy shares of Prana Biotechnology? Shares of PRAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Prana Biotechnology's stock price today? One share of PRAN stock can currently be purchased for approximately $2.2150. How big of a company is Prana Biotechnology? Prana Biotechnology has a market capitalization of $19.93 million and generates $100,000.00 in revenue each year. The biotechnology company earns $-5,680,000.00 in net income (profit) each year or ($0.64) on an earnings per share basis. Prana Biotechnology employs 9 workers across the globe. How can I contact Prana Biotechnology? Prana Biotechnology's mailing address is LEVEL 2 369 ROYAL PARADE, PARKVILLE C3, 3052. The biotechnology company can be reached via phone at 61-3-9349-4906 or via email at [email protected] MarketBeat Community Rating for Prana Biotechnology (NASDAQ PRAN)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 102 (Vote Outperform)Underperform Votes: 121 (Vote Underperform)Total Votes: 223MarketBeat's community ratings are surveys of what our community members think about Prana Biotechnology and other stocks. Vote "Outperform" if you believe PRAN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRAN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/22/2018 by MarketBeat.com StaffFeatured Article: Should you buy a closed-end mutual fund?